================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 3, 2004
-----------
Pharmion Corporation
--------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
-------- --------- ----------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
- ----------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
------------
- --------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibit 99.1 - Press Release dated May 3, 2004.
This exhibit is furnished pursuant to Item 12 and shall not be deemed
to be "filed."
Item 12. Disclosure of Results of Operations and Financial Condition
On May 3, 2004, the Pharmion Corporation issued a press release
relating to the Company's earnings for the quarter ended March 31,
2004. A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K. The information in this Form 8-K and the
exhibit attached hereto shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act")
or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: By: /s/ Erle T. Mast
-------------------
Erle T. Mast
Chief Financial Officer
2
EXHIBIT INDEX
Exhibit No. Description
99.1 Press release dated May 3, 2004 announcing results for the first
quarter ended March 31, 2004.
3